Neuropsychological functioning and age-related changes in schizophrenia and/or cocaine dependence

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 40, Issue 1, 2013, Pages 298-305

  Benaiges, Irina ^a   Serra Grabulosa, Josep Maria ^a,b   Adan, Ana ^a,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c Institute for Brain   (Spain)

Author keywords

Age effects; Cocaine dependence; Cognition; Memory functioning; Schizophrenia

Indexed keywords

COCAINE;

ADULT; AGING; ARTICLE; ATTENTION; BRAIN DAMAGE; COCAINE DEPENDENCE; COGNITION; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; DRUG DETOXIFICATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; VERBAL MEMORY;

ADOLESCENT; ADULT; AGE FACTORS; AGING; COCAINE-RELATED DISORDERS; CROSS-SECTIONAL STUDIES; HUMANS; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; REACTION TIME; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84869381094     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.10.016     Document Type: Article

References (59)

1. Allen D.N., Goldstein G., Aldarondo F. Neurocognitive dysfunction in patients diagnosed of schizophrenia and alcoholism. Neuropsychology 2000, 13:62-68.
2. Andreasen N.C., Pressler M., Nopoulos P., Miller D., Ho B-Ch Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010, 67:255-262.
3. Asarnow R.F., McCrimmon D.J. Residual performance deficit in clinically remitted schizophrenics. A marker of schizophrenia?. J Abnorm Psychol 1978, 87(6):597-608.
4. Benaiges I., Prat G., Adan A. Neuropsychological aspects of dual diagnosis. Curr Drug Abuse Rev 2010, 3:175-188.
5. Bowie C.R., Serper M.R., Riggio S., Harvey P.D. Neurocognition, symptomatology, and functional skills in older alcohol-abusing schizophrenia patients. Schizophr Bull 2005, 31(1):175-182.
6. Bozikas V.P., Andreou C. Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. Aust N Z J Psychiatry 2011, 45:93-108.
7. Cooper L., Liberman D., Tucker D., Nuechtertlein K.H., Tsuang S., Barnett H.L. Neurocognitive deficits in the dually diagnosed with schizophrenia and cocaine abuse. Psychiatr Rehabil Skills 1999, 3(2):231-245.
8. Copersino M.L., Serper M.R., Vedhan N., Goldberg B.R., Richarme D., Chou J.C.-Y., et al. Cocaine craving and attentional bias in cocaine dependent schizoprhrenic patients. Psychiatry Res 2004, 128(3):209-218.
9. Coulston C.M., Perdices M., Tennant C.C. The neuropsychology of cannabis and other substance use in schizophrenia: a review of the literature and critical evaluation of methodological issues. Aust N Z J Psychiatry 2007, 41:869-884.
10. Crespo-Facorro B., Rodríguez-Sanchez J.M., Perez-Iglesias M., Mata I., Ayesa R., Ramirez-Bonilla M., et al. Neurocognitive effectiveness of haloperidol, risperidone and olanzapine in first-episode psychosis: a randomized controlled 1-year follw-up comparison. J Clin Psychiatry 2009, 70:717-729.
11. Drake A.I., Butters N., Shear P.K., Smith T.L., Bondi M., Irwin M., et al. Cognitive recovery with abstinence and its relationship to family history for alcoholism. J Stud Alcohol 1994, 104-109.
12. First M.B., Spitzer R.L., Gibbon M., William J.B.W. Structural Clinical Interview for Axis-I DSM-IV Disorders, Patient's edition 1998, Biometric Research Department, New York state Psychiatric Institute, New York, NY.
13. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 1996, 153:321-330.
14. Harvey P.D., Green M.F., Keefe R.S., Velligan D.I. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 2004, 65:361-372.
15. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerström K.O. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br J Addict 1991, 86:1119-1127.
16. Herman M. Neurocognitive functioning and quality of life among dually diagnosed patients and non substance-abusing schizophrenia inpatients. Int J Ment Health Nurs 2004, 13:282-291.
17. Hill S.K., Schuepbach D., Herbener E.S., Keshavan M.S., Sweeney J.A. Pretreatment and longitudinal studies of neuropsychological deficits of antipsychotics-naïve patients with schizophrenia. Schizophr Res 2004, 68:49-63.
18. Joyal C.C., Hallé P., Lapierre D., Hodgins S. Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophr Res 2003, 63:297-299.
19. Kavanagh D.J., McGrath J., Saunders J.B., Dore G., Clark D. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 2002, 62(5):743-755.
20. Keefe R.S., Seidman L.J., Christensen B.K., Sharma T., Sitskoorn M.M., Rock S.L., et al. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first episode psychosis. Biol Psychiatry 2006, 59:97-105.
21. Keefe R.S., Sweeney J.A., Gu H., Hamer R.M., Perkins D.O., McEvoy J.P., et al. Effects of olanzapine, quetiapine and risperidone on neurocognitive function in early psychosis: a randomized double-blind 52 week comparisons. Am J Psychiatry 2007, 164:1061-1071.
22. Kopala L.C., Good K.P., Milliken H., Buiteman C., Woodley H., Rui Q., et al. Treatment of a first episode psychotic illness with quetiapine: An analysis of 2 years outcome. Schizophr Res 2006, 81:29-39.
23. Kumari V., Postma P. Nicotine use in schizophrenia: the self-medication hypotheses. Neurosci Biobehav Rev 2005, 29:1021-1034.
24. Lewandowski K.E., Cohen B.M., Öngur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychol Med 2011, 41:225-241.
25. Lezak M.D., Howieson D.B., Loring D.W. Neuropsychological assessment 2004, Oxford University Press, Oxford. 4th edition.
26. Manning V., Wanigaratne S., Best D., Strathdee G., Schrover I., Gossop M. Screening for cognitive functioning in psychiatric outpatients with schizophrenia, alcohol dependence and dual diagnosis. Schizophr Res 2007, 91:151-158.
27. Matza L.S., Buchanan R., Purdon S., Brewster-Jordan J., Zhao Y., Revicki D.A. Measuring changes in functional status among patients with schizophrenia: the link with cognitive impairment. Schizophr Bull 2006, 32(4):666-678.
28. Mohamed S., Bondi M.W., Kasckow J.W., Golshan S., Jeste D.V. Neurocognitive functioning in dually diagnosed middle aged and elderly patients with alcoholism and schizophrenia. Int J Geriatr Psychiatry 2006, 21:711-718.
29. Mueser K.T., McGurk S.R. Cognitive functioning in schizophrenia and co-ocurring substance use disorders: where do we go from here?. J Dual Diagn 2012, 8(1):48-49.
30. National Institute of Mental Health CGI. Clinical global impression. Manual for the EDCEU Assessment Battery. 2. rev. ed 1976, Chevy Chase, Maryland. W. Guy, R.R. Bonato (Eds.).
31. O'Malley S., Adamse M., Heaton R.K., Gawin F.H. Neuropsychological impairment in chronic cocaine abusers. Am J Drug Alcohol Abuse 1992, 18(2):131-144.
32. Parsons L.H., Koob G.F., Weiss F. Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine. J Pharmacol Exp Ther 1995, 274:1182-1192.
33. Potvin S., Briand C., Prouteau A., Bouchard R.H., Lipp O., Lalonde P., et al. CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain Cogn 2005, 59(1):38-42.
34. Potvin S., Joyal C.C., Pelletier J., Stip E. Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr Res 2008, 100:242-251.
35. Potvin S., Stavro K., Pelletier J. Paradoxical cognitive capacities in dual diagnosis schizophrenia: the quest of explanatory factors. J Dual Diagn 2012, 81(1):35-47.
36. Purdon S.E., Jones B.D., Stip E., Labelle A., Addington D., David S.R., et al. Neuropsychological changes in early phases schizophrenia during 12 months of treatment with olanzapine, risperidone or haloperidol. The Canadian collaborative group for research in schizophrenia. Arch Gen Psychiatry 2000, 57:249-258.
37. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the epidemiological catchment area (ECA) study. JAMA- J Am Med Assoc 1990, 264:2511-2518.
38. Reitan R.M., Wolfson D. The Healsted-Reitan neuropsychological test battery 1985, Neuropsychological Press, Tucson.
39. Rundt B.R., Melle I., Friis S., Johannessen J.O., Larsen T.K., Midboe L.J., et al. The course of neurocognitive functioning in first episode psychosis and its relation to premorbid adjustment, duration of untreated psychosis, and relapse. Schizophr Res 2007, 91:132-140.
40. Serge S., Stanley R.K., Lewis A.O., Herman M. Significance of cocaine history in schizophrenia. J Nerv Ment Dis 1990, 178(10):642-648.
41. Sakyn A.J., Shtasel D.L., Gur R.E., Kester B., Mozley L.H., Stafiniak P., et al. Neuropsychological deficits in neuroleptic naïve patients with first-episode schizophrenia. Arch Gen Psychiatry 1994, 51:124-131.
42. Schmidt M. Rey auditory Verbal Learning Test: A Handbook 2011, Psychological Assessment Resources, Lutz, FL.
43. Schnell T., Koethe D., Daumann J., Gouzoulis-Mayfrank E. The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology 2009, 205(1):45-52.
44. Scholes K.E., Martin-Iverson M.T. Cannabis use and neuropsychological performance in healthy individuals and patients with schizophrenia. Psychol Med 2010, 40(10):1635-1646.
45. Serper M.R., Bergman A., Copersino M.L., Chou J., Richarme D., Cancro R.a Learning and memory impairment in cocaine-dependent and comorbid schizophrenic patients. Psychiatry Res 2000, 93:21-32.
46. Serper M.R., Copersino M.L., Richarme D., Vandham N., Cranco R. b. Neurocognitive functioning in recently abstinent, cocaine-abusing schizophrenic patients. J Subst Abuse 2000, 11(2):205-213.
47. Sevy S., Kay S.R., Opler L., Van Praag H.M. Significance of cocaine history in schizophrenia. J Nerv Ment Dis 1990, 178(10):642-648.
48. Sevy S., Burdick K.E., Visweswaraiah H., Abdelmessih S., Lukin M., Yechiam E., et al. Iowa Gambling task in schizophrenia and co-occurring cannabis use disorders. Schizophr Res 2007, 92:74-84.
49. Smelson D.A., Davis C.W., Dipano R., Johnson V., Losonczy M.F., Ziedonis D. Executive and motor skill functioning among cocaine dependent schizophrenics and non-drug abusing schizophrenics. J Nerv Ment Dis 2002, 190:200-202.
50. Smelson D.A., Davis C.W., Einstein N., Engelhart C., Williams J., Losonczy M., et al. Cognitive disparity in schizophrenics with and without cocaine dependence. J Subst Abuse Treat 2003, 24(1):75-79.
51. Spreen O., Strauss E. A Compendium of Neuropsychological tests. Administration, Norms and Commentary 1998, Oxford University Press, New York.
52. Stirling J., Lewis S., Hopkins R., White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10 year follow-up. Schizophr Res 2005, 75:135-137.
53. Thoma P., Daum I. Working memory and multi-tasking in paranoid schizophrenia with and without comorbid substance use disorders. Addiction 2008, 103(5):774-786.
54. Thoma P., Wiebel B., Daum I. Response inhibition and cognitive flexibility in schizophrenia with and without comorbid substance use disorder. Schizophr Res 2007, 92:168-180.
55. Tönne U., Hiltunen A.J., Vikander B., Engelbrektsson K., Bergman H., Bergman I., et al. Neuropsychological changes during steady-state drug use withdrawal and abstinence in primary benzodiazepine-dependent patients. Acta Psychiatr Scand 1995, 91:299-304.
56. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Gatley S.J., Hitzemann R., et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997, 386:830-833.
57. Wechsler D. Wechsler Adult Intelligence Scale-revised 2001, TEA ediciones, Madrid, [Spanish Version].
58. Wolwer W., Brinkmeyer J., Riesbeck M., Freimüller L., Klimke A., Wagner M., et al. Neuropsychological impairments predict the clinical course of schizophrenia. Eur Arch Clin Neurosci 2008, 258(5):28-34.
59. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003, 64(6):663-667.